Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6620 in combination with chemotherapy for advanced solid tumors
NCT02157792Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Dec 2012
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of berzosertib in solid tumor, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 1 more, sponsored by EMD Serono. Started Dec 2012; status: completed.
02
Drugs
berzosertib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02157792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157792.